ANDA Pre-Submission Meetings A 'Challenge' To Integrate Into Development Timelines
Executive Summary
US FDA officials appears worried about workload created by product development and pre-submission meetings for complex generics.
You may also be interested in...
GDUFA III May Rely Less On PDUFA As A Role Model
Meeting opportunities codified in GDUFA II were adapted from the new drug user fee program experience but may not be well suited to the commodified generic drug industry built on volume and speed, industry representatives said at the recent FDLI annual meeting.